

## Special Issue

# Hidradenitis Suppurativa (HS): Research Advances in Pathogenesis, Diagnosis and Treatment

### Message from the Guest Editor

Hidradenitis Suppurativa (HS) is increasingly recognised as one of the main dermatological disorder in western countries. The diagnosis is far from being simple as dermatologists have to look for the presence of chronic and unremitting nodules, abscesses, sinus tracts in skin folds, as the only criteria to diagnose HS. Poor knowledge of HS pathogenesis reflects the lack of an effective treatment. Most patients receive a first treatment combining analgesics and topical and systemic antibiotics with HS often mistaken for a folliculitis. Some dermatologists prescribe sulfonamides, immunosuppressants or isotretinoin, used to treat acne. Adalimumab (an anti-TNF- $\alpha$ ) is currently used off-label for severe to moderate cases, although not all the patients respond to the treatment. Medical treatments seldom result in a cure and the aggravation of lesions often lead to surgical resection of the skin of affected areas. Over the last few years however, research in to HS pathogenesis has sensibly increased giving new hopes for a faster diagnosis and effective treatments. The present Special Issue aims to present the last findings in HS pathogenesis that can improve its diagnosis and treatment.

### Guest Editor

Dr. Michele Boniotto  
Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France

### Deadline for manuscript submissions

closed (20 November 2021)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/67439](https://mdpi.com/si/67439)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com/)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).